In Other News

PBS listing recommendations for IFX SC and guselkumab The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of subcutaneous infliximab for the treatment of severe active rheumatoid arthritis (RA), as an alternative to the IV form.  However the PBAC did not  recommend PBS listing of IFX SC for ankylosing spondylitis (AS), severe active psoriatic ...

Already a member?

Login to keep reading.

© 2021 the limbic